• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Dapagliflozin and metabolic dysfunction-associated steatohepatitis.达格列净与代谢功能障碍相关脂肪性肝炎
BMJ. 2025 Jun 4;389:r1101. doi: 10.1136/bmj.r1101.
2
Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial.达格列净对代谢功能障碍相关脂肪性肝炎的影响：多中心、双盲、随机、安慰剂对照试验。
BMJ. 2025 Jun 4;389:e083735. doi: 10.1136/bmj-2024-083735.
3
Effectiveness and risks of dapagliflozin in treatment for metabolic dysfunction-associated steatotic liver disease with type 2 diabetes: a randomized controlled trial.达格列净治疗2型糖尿病合并代谢功能障碍相关脂肪性肝病的有效性和安全性：一项随机对照试验
Front Med (Lausanne). 2025 Mar 25;12:1542741. doi: 10.3389/fmed.2025.1542741. eCollection 2025.
4
Dapagliflozin improves steatohepatitis in diabetic rats via inhibition of oxidative stress and inflammation.达格列净通过抑制氧化应激和炎症改善糖尿病大鼠的脂肪性肝炎。
Int Immunopharmacol. 2022 Mar;104:108503. doi: 10.1016/j.intimp.2021.108503. Epub 2022 Jan 5.
5
Effects of Dapagliflozin on Body Composition and Liver Tests in Patients with Nonalcoholic Steatohepatitis Associated with Type 2 Diabetes Mellitus: A Prospective, Open-label, Uncontrolled Study.达格列净对2型糖尿病相关非酒精性脂肪性肝炎患者身体成分和肝功能检查的影响：一项前瞻性、开放标签、非对照研究。
Curr Ther Res Clin Exp. 2017 Jul 8;87:13-19. doi: 10.1016/j.curtheres.2017.07.002. eCollection 2017.
6
Dapagliflozin protects against nonalcoholic steatohepatitis in db/db mice.达格列净可预防db/db小鼠的非酒精性脂肪性肝炎。
Front Pharmacol. 2022 Aug 19;13:934136. doi: 10.3389/fphar.2022.934136. eCollection 2022.
7
Efficacy and safety of dapagliflozin compared to pioglitazone in diabetic and non-diabetic patients with non-alcoholic steatohepatitis: A randomized clinical trial.达格列净与吡格列酮治疗糖尿病和非糖尿病非酒精性脂肪性肝炎患者的疗效和安全性：一项随机临床试验。
Clin Res Hepatol Gastroenterol. 2025 Mar;49(3):102543. doi: 10.1016/j.clinre.2025.102543. Epub 2025 Jan 29.
8
New Insights on Using Oral Semaglutide versus Dapagliflozin in Patients with Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease.口服司美格鲁肽与达格列净治疗2型糖尿病合并代谢功能障碍相关脂肪性肝病的新见解
Diagnostics (Basel). 2024 Jul 10;14(14):1475. doi: 10.3390/diagnostics14141475.
9
SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice.达格列净通过抑制 SGLT2 改善 2 型糖尿病小鼠的全身性血管功能障碍并改变肠道微生物群。
Cardiovasc Diabetol. 2018 Apr 27;17(1):62. doi: 10.1186/s12933-018-0708-x.
10
Effects of Sodium-Glucose Cotransporter 2 Inhibition on Glucose Metabolism, Liver Function, Ascites, and Hemodynamics in a Mouse Model of Nonalcoholic Steatohepatitis and Type 2 Diabetes.钠-葡萄糖共转运蛋白 2 抑制剂对非酒精性脂肪性肝炎和 2 型糖尿病小鼠模型糖代谢、肝功能、腹水和血液动力学的影响。
J Diabetes Res. 2020 Dec 27;2020:1682904. doi: 10.1155/2020/1682904. eCollection 2020.

本文引用的文献

1
Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial.达格列净对代谢功能障碍相关脂肪性肝炎的影响：多中心、双盲、随机、安慰剂对照试验。
BMJ. 2025 Jun 4;389:e083735. doi: 10.1136/bmj-2024-083735.
2
Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.司美格鲁肽治疗代谢功能障碍相关脂肪性肝炎的3期试验
N Engl J Med. 2025 Jun 5;392(21):2089-2099. doi: 10.1056/NEJMoa2413258. Epub 2025 Apr 30.
3
EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).EASL-EASD-EASO 临床实践指南：代谢功能障碍相关脂肪性肝病（MASLD）的管理。
J Hepatol. 2024 Sep;81(3):492-542. doi: 10.1016/j.jhep.2024.04.031. Epub 2024 Jun 7.
4
Opportunities and challenges following approval of resmetirom for MASH liver disease.玛仕肝脏疾病（MASH）药物resmetirom获批后的机遇与挑战。
Nat Med. 2024 Dec;30(12):3402-3405. doi: 10.1038/s41591-024-02958-z.
5
Pharmacological Approaches to Nonalcoholic Fatty Liver Disease: Current and Future Therapies.非酒精性脂肪性肝病的药理学治疗方法：当前与未来的疗法
Diabetes Spectr. 2024 Winter;37(1):48-58. doi: 10.2337/dsi23-0012. Epub 2024 Feb 15.
6
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.一项评估 Resmetirom 治疗伴有肝纤维化的 NASH 的 3 期随机对照试验。
N Engl J Med. 2024 Feb 8;390(6):497-509. doi: 10.1056/NEJMoa2309000.
7
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease.美国肝病研究学会非酒精性脂肪性肝病临床评估与管理实践指南
Hepatology. 2023 May 1;77(5):1797-1835. doi: 10.1097/HEP.0000000000000323. Epub 2023 Mar 17.
8
The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review.非酒精性脂肪性肝病（NAFLD）和非酒精性脂肪性肝炎（NASH）的全球流行病学：系统评价。
Hepatology. 2023 Apr 1;77(4):1335-1347. doi: 10.1097/HEP.0000000000000004. Epub 2023 Jan 3.
9
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.达格列净治疗射血分数轻度降低或保留的心力衰竭。
N Engl J Med. 2022 Sep 22;387(12):1089-1098. doi: 10.1056/NEJMoa2206286. Epub 2022 Aug 27.
10
The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis.全球非酒精性脂肪性肝病的患病率和发病率：系统评价和荟萃分析。
Lancet Gastroenterol Hepatol. 2022 Sep;7(9):851-861. doi: 10.1016/S2468-1253(22)00165-0. Epub 2022 Jul 5.

达格列净与代谢功能障碍相关脂肪性肝炎

Dapagliflozin and metabolic dysfunction-associated steatohepatitis.

作者信息

Haddad Leila, Marciano Sebastián

机构信息

Liver Unit, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

Liver Unit, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.

出版信息

BMJ. 2025 Jun 4;389:r1101. doi: 10.1136/bmj.r1101.

DOI:10.1136/bmj.r1101
PMID:40467092
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12153409/
Abstract

Improves fibrosis and steatohepatitis

摘要

改善纤维化和脂肪性肝炎